| abstract |
The invention relates to a pharmaceutical combination comprising (a) an RTK inhibitor selected from the group consisting of a compound of formula I or a tautomer thereof, a compound of formula II or a tautomer thereof, a compound of formula III or a tautomer thereof a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt of the tautomer or a mixture thereof; and (b) one or more CYP17 inhibitors, such as abiraterone; and treatment A method of afflicting an individual with a proliferative disorder comprising administering a combination of a therapeutically effective amount. |